Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.46 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.46 |
| ▸ | GPR6 | P46095 | 8/20 | 0.44 |
| ▸ | BCL6 | P41182 | 2/20 | 0.41 |
| ▸ | FPR2 | P25090 | 2/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4836323 | 0.90 | FPR2 (0.45) | GPR6FPR2PROKR1AURKAPIK3CD | |
| SCHEMBL14293851 | 0.88 | EHMT2 (0.39) | EHMT2EHMT1GPR6AURKAAURKB | |
| SCHEMBL4832649 | 0.85 | BCL6 (0.49) | EHMT2EHMT1BCL6AURKAAURKB | |
| SCHEMBL5550604 | 0.84 | PIK3CD (0.39) | EHMT2EHMT1GPR6BCL6FPR2 | |
| SCHEMBL5030662 | 0.84 | EHMT2 (0.49) | EHMT2EHMT1BCL6AURKAAURKB | |
| SCHEMBL6234397 | 0.82 | EHMT2 (0.53) | EHMT2EHMT1BCL6AURKAAURKB | |
| SCHEMBL4829397 | 0.81 | EHMT2 (0.42) | EHMT2EHMT1GPR6FPR2PROKR1 | |
| SCHEMBL5431636 | 0.80 | GALR1 (0.49) | EHMT2BCL6AURKAMAPT | |
| SCHEMBL4829119 | 0.78 | SRC (0.44) | BCL6AURKA | |
| SCHEMBL6209284 | 0.78 | PDGFRB (0.39) | GPR6FPR2PROKR1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169784-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | claimed |
| US-7163943-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-16 | — | — | US | claimed |
| EP-1560817-A1 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | Reddy US Therapeutics, Inc. (US) | 2005-08-10 | — | — | EP | claimed |
| US-20050137196-A1 | Medical devices employing triazine compounds and compositions thereof | NATIONAL BANK OF CANADA (CA) | 2005-06-23 | — | — | US | claimed |
| WO-2004026844-A9 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS INC (US) | 2004-11-11 | — | — | WO | claimed |
| US-20040209880-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-10-21 | — | — | US | claimed |
| WO-2004026844-A1 | METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS | REDDY US THERAPEUTICS, INC. (US) | 2004-04-01 | — | — | WO | claimed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332489-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-7169784-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169784-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169784-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20050137196-A1 | Medical devices employing triazine compounds and compositions thereof | NATIONAL BANK OF CANADA (CA) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099874-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | EHMT2 2905/4885EHMT1 2811/4885GPR6 1292/4885 |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | EHMT2 2905/4885EHMT1 2811/4885GPR6 1292/4885 |
| US-20050137196-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | EHMT2 2474/4885EHMT1 2630/4885GPR6 1040/4885 |
| US-20040209880-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | EHMT2 2905/4885EHMT1 2811/4885GPR6 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.